# Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

> **NCT04446416** · NA · COMPLETED · sponsor: **NaviFUS Corporation** · enrollment: 6 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- Glioma
- Brain Tumor
- Neoplasms
- Neoplasms, Nerve Tissue

## Interventions

- **DEVICE:** NaviFUS System
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04446416
- **Lead sponsor:** NaviFUS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-21
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-08-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446416, "Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04446416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*